NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free TOVX Stock Alerts $0.42 +0.02 (+5.03%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4450-Day Range N/A52-Week Range$0.20▼$1.20Volume50,772 shsAverage Volume114,650 shsMarket Capitalization$7.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesShort Interest Get Theriva Biologics alerts: Email Address Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About Theriva Biologics Stock (NYSEAMERICAN:TOVX)Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.Read More TOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TOVX Stock News HeadlinesMay 7, 2024 | investorplace.comTOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024May 7, 2024 | globenewswire.comTheriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial ResultsMay 8, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 25, 2024 | investing.comTheriva reports progress in retinoblastoma treatment trialApril 25, 2024 | globenewswire.comTheriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | globenewswire.comTheriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory RetinoblastomaApril 22, 2024 | globenewswire.comTheriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 17, 2024 | benzinga.comTheriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat CancersMay 8, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 8, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 8, 2024 | globenewswire.comTheriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingMarch 27, 2024 | seekingalpha.comTheriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comQ4 2023 Theriva Biologics Inc Earnings CallMarch 25, 2024 | globenewswire.comTheriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial ResultsMarch 22, 2024 | benzinga.comPreview: Theriva Biologics's EarningsMarch 19, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 19, 2024 | globenewswire.comTheriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 11, 2024 | globenewswire.comTheriva™ Biologics to Participate in the BIO-Europe Spring ConferenceFebruary 8, 2024 | msn.comTheriva Biologics Reports Positive Phase 2b Trial ProgressFebruary 8, 2024 | msn.comTheriva Biologics VIRAGE Trial Progresses PositivelyFebruary 7, 2024 | finance.yahoo.comTheriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaJanuary 16, 2024 | finance.yahoo.comTheriva Biologics to Participate in the B. Riley Securities Annual Oncology ConferenceNovember 20, 2023 | finance.yahoo.comTheriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comQ3 2023 Theriva Biologics Inc Earnings CallNovember 13, 2023 | msn.comTheriva Biologics GAAP EPS of -$0.19 beats by $0.23November 13, 2023 | finance.yahoo.comTheriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial ResultsNovember 10, 2023 | msn.comTheriva Biologics Q3 2023 Earnings PreviewSee More Headlines Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/07/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:TOVX CUSIPN/A CIKN/A Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.93% Return on Assets-29.35% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.19Miscellaneous Outstanding Shares17,280,000Free Float16,367,000Market Cap$7.22 million OptionableNot Optionable Beta1.48 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Steven A. Shallcross CPA (Age 63)CEO, CFO, Treasurer, Corporate Secretary & Director Comp: $993.46kDr. Vince Wacher Ph.D.Head of Product & Corporate DevelopmentDr. Michael Kaleko M.D.Ph.D., Senior Vice President of Research & DevelopmentDr. Ramon Alemany Ph.D.Senior VP of Discovery & Chairman of Scientific Advisory BoardMs. Lara M. GuzmanSenior Director of Project OperationsKey CompetitorsCan-Fite BioPharmaNYSE:CANFProcessa PharmaceuticalsNASDAQ:PCSATransCode TherapeuticsNASDAQ:RNAZInnovus PharmaceuticalsOTCMKTS:INNVDPasithea TherapeuticsNASDAQ:KTTAView All CompetitorsInsidersSteven A ShallcrossBought 26,000 shares on 6/6/2023Total: $16,380.00 ($0.63/share)View All Insider Transactions TOVX Stock Analysis - Frequently Asked Questions When is Theriva Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TOVX earnings forecast. How were Theriva Biologics' earnings last quarter? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) released its earnings results on Monday, March, 25th. The company reported ($0.32) EPS for the quarter. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:TOVX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024Altimetry[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.